Open AccessThe prognostic value of metformin for advanced non-small cell lung cancer: a systematic review and meta-analysis
Author(s) -
Jianrong Zhang,
JingMing Wu,
Qihua He,
Wenhua Liang,
Jianxing He
Publication year - 2018
Publication title -
translational lung cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 41
eISSN - 2226-4477
pISSN - 2218-6751
DOI - 10.21037/tlcr.2018.03.14
Subject(s) - metformin , medicine , meta analysis , subgroup analysis , lung cancer , hazard ratio , oncology , web of science , diabetes mellitus , non small cell lung cancer (nsclc) , confidence interval , insulin , endocrinology , a549 cell
The prognostic value of Metformin for concurrent non-small cell lung cancer (NSCLC) has been controversial in previous individual studies and meta-analyses. In order to further investigate the value of this medication, we conducted a systematic review and meta-analysis for patients with advanced or inoperable NSCLC.